简介：

简介：AbstractForecasting the COVID-19 confirmed cases, deaths, and recoveries demands time to know the severity of the novel coronavirus. This research aims to predict all types of COVID-19 cases (verified people, deaths, and recoveries) from the deadliest 3rd wave data of the COVID-19 pandemic in Bangladesh. We used the official website of the Directorate General of Health Services as our data source. To identify and predict the upcoming trends of the COVID-19 situation of Bangladesh, we fit the Auto-Regressive Integrated Moving Average (ARIMA) model on the data from Mar. 01, 2021 to Jul. 31, 2021. The finding of the ARIMA model (forecast model) reveals that infected, deaths, and recoveries number will have experienced exponential growth in Bangladesh to October 2021. Our model reports that confirmed cases and deaths will escalate by four times, and the recoveries will improve by five times at a later point in October 2021 if the trend of the three scenarios of COVID-19 from March to July lasts. The prediction of the COVID-19 scenario for the next three months is very frightening in Bangladesh, so the strategic planner and field-level personnel need to search for suitable policies and strategies and adopt these for controlling the mass transmission of the virus.

简介：【摘要】 目的 研究麻醉精神类药品在管理过程中实施处方登记和处方编号管理的价值。方法 选择2019年1月-2021年12月在我院应用麻醉精神类药品进行治疗的患者140例，根据用药治疗期间药品管理模式的不同将其分成对照组和观察组。对照组中70例患者采用常规模式对麻醉精神类药品实施管理；观察组中70例患者采用处方登记和处方编号模式对麻醉精神类药品实施管理。对比两组研究对象对药品管理模式的满意度、不合格处方数、不良反应、纠纷事件情况、麻醉精神类药品应用时间和疾病治疗总时间。结果 观察组研究对象对药品管理模式的满意度高于对照组，组间数据比较差异有统计学意义（P＜0.05）；不合格处方数、不良反应、纠纷事件例数少于对照组，组间数据比较差异有统计学意义（P＜0.05）；麻醉精神类药品应用时间和疾病治疗总时间短于对照组，组间数据比较差异有统计学意义（P＜0.05）。结论 麻醉精神类药品在管理过程中应用处方登记和处方编号模式，可以明显减少不合格处方数和不良反应，使纠纷事件发生率降低，缩短病情治疗时间，使患者满意度得到显著提升。

简介：【摘要】 目的 研究麻醉精神类药品在管理过程中实施处方登记和处方编号管理的价值。方法 选择2019年1月-2021年12月在我院应用麻醉精神类药品进行治疗的患者140例，根据用药治疗期间药品管理模式的不同将其分成对照组和观察组。对照组中70例患者采用常规模式对麻醉精神类药品实施管理；观察组中70例患者采用处方登记和处方编号模式对麻醉精神类药品实施管理。对比两组研究对象对药品管理模式的满意度、不合格处方数、不良反应、纠纷事件情况、麻醉精神类药品应用时间和疾病治疗总时间。结果 观察组研究对象对药品管理模式的满意度高于对照组，组间数据比较差异有统计学意义（P＜0.05）；不合格处方数、不良反应、纠纷事件例数少于对照组，组间数据比较差异有统计学意义（P＜0.05）；麻醉精神类药品应用时间和疾病治疗总时间短于对照组，组间数据比较差异有统计学意义（P＜0.05）。结论 麻醉精神类药品在管理过程中应用处方登记和处方编号模式，可以明显减少不合格处方数和不良反应，使纠纷事件发生率降低，缩短病情治疗时间，使患者满意度得到显著提升。

简介：AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.

简介：无

简介：无

简介：AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1

简介：摘要由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病（COVID-19）已经在全球多个国家引起大流行，该病毒传染性强、致死率高，部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性；不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物，疫情控制需依赖新型冠状病毒疫苗的接种，如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习，展现目前相关研究的进展。

简介：AbstractA large-scale vaccination of coronavirus disease-19 (COVID-19) in adults has been conducted for nearly a year, and there is a growing recognition that immunization for children is also essential. It has been months since emergency use of pediatric COVID-19 vaccine was approved, we reviewed the prevalence and transmission of COVID-19 in children. The prevalence of COVID-19 in children is reduced due to vaccination even in a Delta prevalent period, so an increase in the vaccination rate is needed in children. Although the precise role of children in the transmission requires more research to uncover, they likely played a significant role, according to the available literature. We also described four candidate COVID-19 vaccines for children on their safety and immunogenicity and the impact of severe acute respiratory syndrome coronavirus 2 variants on childhood vaccination. Safety issues on pediatric vaccines post-approval, like adverse events following immunization and adverse events of special interest require studies on long-term and effective regulatory mechanisms.

简介：无

简介：无

简介：AbstractCOVID-19 has been a global health concern since 2019 until date. Global concerted efforts to combat this pandemic has resulted in a number of vaccines distributed across the globe. Although the presence of these vaccines produced quick interventions, dynamic mutation in the causal virus and the continuous evolution of new stains that defy available vaccines has given rise to pertinent questions. The most recent emergence of a new COVID-19 virus variant (omicron), the rapid spread and overwhelming rate of morbidity and mortality has reopened these questions for debate. This commentary summarizes major view on these questions and concludes that multiple approach including social behavioural measures, vaccination and antiviral drug would speed up elimination process.

简介：AbstractObjective:Otolaryngologists are at increased occupational risk of Coronavirus Disease 2019 (COVID-19) infection due to exposure from respiratory droplets and aerosols generated during otologic, nasal, and oropharyngeal examinations and procedures. There have been a variety of guidelines and precautions developed to help mitigate this risk. While many reviews have focused on the personal protective equipment (PPE) and preparation guidelines for surgery in the COVID-19 era, none have focused on the more creative and unusual solutions designed to limit viral transmission. This review aims to fill that need.Data Sources:PubMed, Ovid/Medline, and ScopusMethods:A comprehensive review of literature was performed on September 28, 2020 using PubMed, Ovid/Medline, and Scopus databases. All English-language studies were included if they proposed or assessed novel interventions developed for Otolaryngology practice during the COVID-19 pandemic. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed.Results:A total of 41 papers met inclusion criteria and were organized into 5 categories ('General Recommendations for Otolaryngologic Surgery’, 'Equipment Shortage Solutions’, 'Airway Procedures’, 'Nasal Endoscopy and Skull Base Procedures’, and 'Otologic Procedures’). Articles were summarized, highlighting the innovations created and evaluated during the COVID-19 pandemic. Creative solutions such as application of topical viricidal agents, make-shift mask filters, three-dimensional (3-D) printable adapters for headlights, aerosol containing separation boxes, and a variety of new draping techniques have been developed to limit the risk of COVID-19 transmission.Conclusions:Persistent risk of COVID-19 exposure remains high. Thus, there is an increased need for solutions that mitigate the risk of viral transmission during office procedures and surgeries, especially given that most COVID-19 positive patients present asymptomatically. This review examines and organizes creative solutions that have been proposed and utilized in the otolaryngology. These solutions have a potential to minimize the risk of viral transmission in the current clinical environment and to create safer outpatient and operating room conditions for patients and healthcare staff.

简介：

简介：摘要疫苗接种依然是人类历史上对抗不同病毒感染的最有效干预手段。新型冠状病毒(COVID－19)疫苗在预防COVID－19方面的总体益处已得到充分证实。与此同时，也出现了COVID－19疫苗接种后眼部不良反应的报告，可累及眼部多种组织，如眼睑、角膜、巩膜、视网膜、葡萄膜、神经和血管等，临床表现为角膜炎、葡萄膜炎、视网膜炎、神经麻痹、血管阻塞等。眼科医生应关注COVID－19疫苗接种后眼部不良反应的发生。(国际眼科纵览，2022, 46：385－390)

简介：AbstractThe coronavirus disease 2019 (COVID-19) pandemic has been an unmitigated disaster for society and the economy worldwide. However, much remains unknown about the pathogenesis of, treatment methods for, and preventive measures against COVID-19. Single-cell sequencing is a novel sequencing technology whose use has recently become prevalent in various life-science fields. This high-resolution technology is being used to analyze the COVID-19 pandemic at a single-cell level. In this review, we summarize the application of single-cell sequencing technology to the field of COVID-19-related research, including the biology of severe acute respiratory syndrome coronavirus 2, clinical concerns associated with COVID-19, neutralizing antibody screening, and vaccine development. We also address challenges to, and improvements in, existing single-cell research related to COVID-19.

简介：AbstractMucormycosis is a lethal human disease caused by fungi of the order Mucorales. Mucormycosis is caused by fungi mainly belonging to the genera Mucor, Rhizopus, and Lichtheimia, all of which belong to the order Mucorales. The number of individuals with mucormycosis-causing disorders has increased in recent years, hence, leading to the spread of mucormycosis. Throughout the coronavirus disease 2019 (COVID-19) pandemic, numerous cases of mucormycosis in COVID-19-infected patients have been reported worldwide, and the illness is now recognized as COVID-19-associated mucormycosis, with most of the cases being reported from India. Immunocompromised patients such as those with bone marrow sickness and uncontrolled diabetes are at a greater risk of developing mucormycosis. Genes, pathways, and other mechanisms have been studied in Mucorales, demonstrating a direct link between virulence and prospective therapeutic and diagnostic targets. This review discusses several proteins such as high-affinity iron permease (FTR1), calcineurin, spore coat protein (CotH), and ADP-ribosylation factors involved in the pathogenesis of mucormycosis that might prove to be viable target(s) for the development of novel diagnostic and therapeutic methods.

简介：无

简介：摘要 目的：研究新冠疫情对郑州市脑卒中患者症状、干预措施等的影响。方法：以2019年2月至12月和2020年同期至郑州人民医院卒中中心就诊的患者共计1251例为调查对象，根据郑州人民医院卒中中心提取资料，以2019年2月至12月脑卒中患者752例为对照组，2020年同期499例为观察组。结果：疫情期间脑卒中患者就诊总人数相比疫情前脑卒中就诊总人数较同期下降46.5%( 187例vs100例)。其中农村患者较2019年同期减少73.5%(34例vs9例)。其余疫情前较疫情期间脑卒中患者的一般资料比较差异均无统计学意义(P>0.05)。疫情期间进行多模核磁共振检查的人数减少(P